Untersuchung der Sicherheit von Atezolizumab beim Blasenkarzinom

Drug: Atezolizumab

Inclusion Criteria:

- Participants with histologically documented locally advanced (tumor [T] 4b, any node
[N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial
carcinoma of the urinary tract

- Participants with measurable and/or non-measurable disease according to RECIST v1.1

- Participants must have progressed during or following treatment with at least one
prior (and not more than 3) treatments for inoperable, locally advanced or metastatic
urothelial or non-urothelial carcinoma of the urinary tract

- If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen
block should be submitted

- Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2

Exclusion Criteria:

- Treatment with more than three prior lines of systemic therapy for inoperable, locally
advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

- Treatment with any other investigational agent or participation in another clinical
trial with therapeutic intent within 4 weeks prior to study treatment initiation

1. Participants who were in another clinical trial with therapeutic intent within 4
weeks of study treatment initiation but were not on active drug in that prior
trial are eligible

2. Participants who were in another clinical trial with therapeutic intent within 4
weeks of study treatment initiation but were in the follow-up phase of that prior
trial and had stopped receiving active drug 4 or more weeks before study
treatment initiation are eligible

- Malignancies other than the one studied in this protocol within 5 years prior to Cycle
1, Day 1

- Evidence of significant uncontrolled concomitant disease that could affect compliance
with the protocol

- Significant renal disorder indicating a need for renal transplant